Trials / Completed
CompletedNCT05739110
HCC Staging Modified by Tumor Micronecrosis
Optimizing Hepatocellular Carcinoma Disease Staging Systems by Incorporating Tumor Micronecrosis: A Multi-institutional Retrospective Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,100 (actual)
- Sponsor
- Zhejiang University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Tumor micronecrosis is a pathological feature that reflects malignant biological behavior in hepatocellular carcinoma (HCC). This study aimed to evaluate the prognostic significance of tumor micronecrosis based on the current BCLC and TNM staging systems, and futher improve the performance of the staging models by establishing modified new staging models including tumor micronecrosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | tumor micronecrosis | whether HCC patients have tumor micronecrosis or not |
Timeline
- Start date
- 2022-07-15
- Primary completion
- 2022-12-01
- Completion
- 2023-01-15
- First posted
- 2023-02-22
- Last updated
- 2023-02-22
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05739110. Inclusion in this directory is not an endorsement.